The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
Check out some of NeurologyLive®'s featured content in the carousel below.
February 1st 2023
Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
January 26th 2023After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
Aβ Protofibril Elimination in Alzheimer Disease
January 21st 2023One model of AD suggests that Aβ pathophysiology triggers downstream molecular pathways, including tauopathy, which lead to cortical neurodegeneration, and cognitive decline is further attributed to the associated neurocortical Aβ plaques.
Detecting Cognitive Decline in Underserved Communities Using 5-Cog: Joe Verghese, MBBS, MS
January 10th 2023The director of the Montefiore Einstein Center for the Aging Brain provided insight on how the 5-Cog assessment tool is specifically tailored for people from a range of racial and ethnic background, education levels, and socioeconomic circumstances. [WATCH TIME: 4 minutes]
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
January 6th 2023Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Clinicians Raise Concerns Over Lecanemab Following Patient Death Treated With tPA for Stroke
January 5th 2023In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.